{"id":"https://genegraph.clinicalgenome.org/r/0e364cff-0932-4544-9224-3c8d96c31512v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0e364cff-0932-4544-9224-3c8d96c31512","GCISnapshot":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-06-26T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e324523-b9fd-4fb7-8500-f606a2746042","type":"EvidenceLine","dc:description":"Due to embryonic lethality, the phenotype could not be further analyzed.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6c3cbd4b-d12c-4092-b586-ecc108aa550a","type":"Finding","dc:description":"Histological analysis on 22 embryos (8 HL +/+, 8 HL +/-, 6 HL -/-) showed vacuolization in the liver. Hepatocytes of 2 HL -/- were further analyzed and vacuolization, particularly in the mitochondria, was present. Mitochondria are predicted to be the site of HMG-CoA accumulation in HL deficiency.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9817922","rdfs:label":"KO Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3c1ec35d-d999-42b6-8feb-282872f0ab65","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ca74dba-9c32-47e4-aa73-38f0b7b974cf","type":"Finding","dc:description":"HLLKO mice died between 3 and 5 weeks and appeared normal until 1-3 hours before death. Progressive lethargy, hypoglycemia, and hyperammonemia occurred (Figure 3). Urine organic acids and plasma acylcarnitines were measured under non-stressed conditions, following KIC injection (a transamination product of leucine), and in samples available from spontaneous crises in HLLKO mice. Under stable conditions, HLLKO mice had elevated levels of leucine-related metabolites. In spontaneous crises of HLLKO mice, Krebs cycle and fatty acid derivatives were higher. Under stressed conditions, HLLKO mice showed elevated C5-hydroxylcarnitine, FA-derived acylcarnitines and decreased C4- and C3-acylcarnitines. In HLLKO hepatocytes, acetoacetate production was undetectable. Glucogenesis was measured in vivoby intraperitoneal pyruvate loading. The rapid increase of blood glucose occured in controls but not in HLLKO mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23861731","rdfs:label":"Liver-specific KO in mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e07d9f6-94e9-43af-8994-b98f5832f1b3","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa8f6850-d78e-4d30-962b-33b4963727f0","type":"FunctionalAlteration","dc:description":"HMG-CoA lyase activity in cultured fibroblasts derived from AMS showed 3, 6, and 1% of activity compared to control in 3 different replicates.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3128690","rdfs:label":"HMG-CoA lyase activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08603209-b6d7-45ab-9af3-3a8d9fb34334","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75bb8ae2-0650-4179-b568-453320371b4a","type":"Finding","dc:description":"The deficiency in humans results in episodes of hypoketotic hypoglycemia, which a decreased concentration of glucose in the blood associated with a reduced concentration of ketone bodies.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8617516","rdfs:label":"Ketogenesis","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/febce124-2981-4740-a4a0-ec16352ab603","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd2e34f9-e6b1-4b49-b2c9-abc9493b0490","type":"Finding","dc:description":"HL mRNA and activity was measured in liver, kidney, pancreas, testis, heart, brain, and skeletal muscle. Expression and activity were significantly higher in liver than any other tissue.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20532825","rdfs:label":"HL expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5},{"id":"https://genegraph.clinicalgenome.org/r/f4d084e5-a740-4bfd-a850-d6db900d4a4e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/756e3139-f13d-4fb9-a09f-7a49cce5401e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15535a5e-59a7-4ad9-a497-82969dac39db","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","rdfs:label":"Patient 3","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":3,"detectionMethod":"Genomic DNA and total RNA extracted from blood or fibroblasts. All exons and exon-intron boundaries PCR amplified and Sanger sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"HMGCLD diagnosis based on characteristic metabolite findings. \"2 metabolic decompensations\", deficient in fibroblasts.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/756e3139-f13d-4fb9-a09f-7a49cce5401e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","allele":{"id":"https://genegraph.clinicalgenome.org/r/5e4c8359-242b-4e29-b63d-60672212a668","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.876+1G>C (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339020821"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ad271f71-54d4-4f23-a3e7-c0bd140c75bd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expressed variant in E. coli and performed HL assay. Activity (nmol acetoacetate/min/mg protein) was less than 5% of wild type and Km (HMG-CoA, uM) was not detectable.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/030140e0-92fb-473f-bddc-96414e03d1da","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","rdfs:label":"Patient 13","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"Entire coding region sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"14 out of 24 patients showed elevation of organic acids in urine.","phenotypes":["obo:HP_0001942","obo:HP_0000707","obo:HP_0001985"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ad271f71-54d4-4f23-a3e7-c0bd140c75bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","allele":{"id":"https://genegraph.clinicalgenome.org/r/853ec455-d5a8-4070-b38b-78210cfa6cc5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.598A>T (p.Ile200Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339024374"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e9e88de5-dfcb-473e-8987-52003a1ab0ed_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c54cb660-e6c0-4fdf-810e-18d3a420ff37","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","rdfs:label":"Patient 5","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":4,"detectionMethod":"Genomic DNA and total RNA extracted from blood or fibroblasts. All exons and exon-intron boundaries PCR amplified and Sanger sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"HMGCLD diagnosis based on characteristic metabolite findings. \"2 metabolic decompensations,\" deficient in EBV-transformed lymphoblastoid cells.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e9e88de5-dfcb-473e-8987-52003a1ab0ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","allele":[{"id":"https://genegraph.clinicalgenome.org/r/775090cf-85f6-4b34-8be4-6d7aba545448","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.308_317dup (p.Thr107ProfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA521650914"}},{"id":"https://genegraph.clinicalgenome.org/r/ad521365-6200-4def-8ef5-7f8cf8592fca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.27del (p.Arg10GlyfsTer24)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA521652907"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d53c52e1-c2d8-4c58-9ca8-a04f068c2b46_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Mutation causes a frameshift within Ser-69 codon and is predicted to produce a 78-residue peptide, 8 of the last 10 residues differing from normal HL. Termination at nucleotides 237-239. Northern analysis showed a small amount of mRNA.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/001322cf-c836-4c82-9311-ef78027c0929","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8440722","rdfs:label":"Sibling 1","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP analysis using cDNA found abnormal migration of a fragment spanning residues 557 to 756. Direct sequencing was performed on this region.","phenotypeFreeText":"In lymphocytes, had 0% of control HL enzyme activity. Northern analysis showed severely reduced amounts of normal sized mRNA (Figure 3).","phenotypes":["obo:HP_0001325","obo:HP_0001992","obo:HP_0001958","obo:HP_0001254"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d53c52e1-c2d8-4c58-9ca8-a04f068c2b46_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8440722","allele":{"id":"https://genegraph.clinicalgenome.org/r/fe2c5bc7-a9fd-43df-9aa8-125a017b0cac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.206_207delCT (p.Ser69Cysfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11954"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d4b177c7-722b-41ee-aedd-a8b51f81e25e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expressed variant in E. coli and performed HL assay. Activity (nmol acetoacetate/min/mg protein) was less than 5% of wild type and Km (HMG-CoA, uM) was not detectable.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c03a2713-b1a3-40b7-80a4-25fad0ee332b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","rdfs:label":"Patient 8","ageType":"AgeAtOnset","ageUnit":"Years","detectionMethod":"Entire coding region sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"14 out of 24 patients showed elevation of organic acids in urine.","phenotypes":["obo:HP_0001942","obo:HP_0002240","obo:HP_0001985"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d4b177c7-722b-41ee-aedd-a8b51f81e25e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","allele":{"id":"https://genegraph.clinicalgenome.org/r/c6ab2ac0-0324-483f-9a38-a939b52255c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.109G>A (p.Glu37Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339030391"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d1006d20-64b1-4a94-891b-5795a91dcc6b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1320ef82-7fd5-4702-8c90-c1d56b5a07c4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","rdfs:label":"Patient 10","ageType":"AgeAtOnset","ageUnit":"Years","detectionMethod":"Entire coding region sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"14 out of 24 patients showed elevation of organic acids in urine.","phenotypes":["obo:HP_0001985","obo:HP_0002240","obo:HP_0001942","obo:HP_0002910"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d1006d20-64b1-4a94-891b-5795a91dcc6b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","allele":{"id":"https://genegraph.clinicalgenome.org/r/065d1c64-f015-495a-9254-7fff81878dc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.242G>A (p.Trp81Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339028998"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/de3b71cd-54e1-4658-a861-ead0f7eea4c6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expressed variant in E. coli and performed HL assay. Activity (nmol acetoacetate/min/mg protein) was less than 5% of wild type and Km (HMG-CoA, uM) was not detectable.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e15ec44-a824-473a-b714-fd7957b92fd8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","rdfs:label":"Patient 11","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"Entire coding region sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"14 out of 24 patients showed elevation of organic acids in urine.","phenotypes":["obo:HP_0001942","obo:HP_0001985"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/de3b71cd-54e1-4658-a861-ead0f7eea4c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","allele":{"id":"https://genegraph.clinicalgenome.org/r/d6bbfcef-e644-4f05-9cb5-98c21a580d38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.521G>A (p.Cys174Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA686065"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/55222653-e7c9-4fd9-89d9-268f029367df_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d49f9f4-291d-423f-a1c6-8f279ee17085","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","rdfs:label":"Patient 6","ageType":"AgeAtDiagnosis","ageUnit":"Days","ageValue":3,"detectionMethod":"Genomic DNA and total RNA extracted from blood or fibroblasts. All exons and exon-intron boundaries PCR amplified and Sanger sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"HMGCLD diagnosis based on characteristic metabolite findings. \"1 metabolic decompensation.\"","phenotypes":"obo:HP_0010864","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/55222653-e7c9-4fd9-89d9-268f029367df_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28583327","allele":{"id":"https://genegraph.clinicalgenome.org/r/c8caa18e-0d71-4a02-a90b-d36887ea2512","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.658del (p.Ala220LeufsTer27)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820586"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/58a23d86-7c22-47ed-b6c4-be053c06ba58_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expressed variant in E. coli and performed HL assay. Activity (nmol acetoacetate/min/mg protein) was less than 5% of wild type and Km (HMG-CoA, uM) was not detectable.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2657e623-837f-4348-92d2-2e21b4a1791d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","rdfs:label":"Patient 12","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"Entire coding region sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"14 out of 24 patients showed elevation of organic acids in urine.","phenotypes":["obo:HP_0001942","obo:HP_0001985"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/58a23d86-7c22-47ed-b6c4-be053c06ba58_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19177531","allele":{"id":"https://genegraph.clinicalgenome.org/r/1686b6b5-1c03-4748-b9cc-1ab7d2ae8812","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000191.2(HMGCL):c.575T>C (p.Phe192Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA339024521"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":386,"specifiedBy":"GeneValidityCriteria6","strengthScore":16.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/7oJV6K1AHB0","type":"GeneValidityProposition","disease":"obo:MONDO_0009520","gene":"hgnc:5005","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_f4d084e5-a740-4bfd-a850-d6db900d4a4e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}